- Patent Title: Fused Tricyclic imidazole derivatives as modulators of TNF activity
-
Application No.: US15101798Application Date: 2014-12-08
-
Publication No.: US09890174B2Publication Date: 2018-02-13
- Inventor: Rikki Peter Alexander , Julien Alistair Brown , Michael Deligny , Jag Paul Heer , Victoria Elizabeth Jackson , Sophie Jadot , Boris Kroeplien , Malcolm Mac Coss , Yogesh Anil Sabnis , Dominique Louis Léon Swinnen , Nathalie Van Houtvin , Zhaoning Zhu
- Applicant: UCB BIOPHARMA SPRL
- Applicant Address: BE Brussels
- Assignee: UCB BIOPHARMA SPRL
- Current Assignee: UCB BIOPHARMA SPRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB1321730.2 20131209
- International Application: PCT/EP2014/076886 WO 20141208
- International Announcement: WO2015/086527 WO 20150618
- Main IPC: C07D491/14
- IPC: C07D491/14 ; C07D471/04 ; A61K31/437 ; A61K31/4375 ; C07D491/147 ; C07D471/14

Abstract:
A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c′]dipyridine, dihydro-1H-pyrano[3′,4′:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20160304530A1 Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity Public/Granted day:2016-10-20
Information query